Navigation Links
Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Date:1/24/2013

"Late-Stage Development fourth quarter revenues grew 15.7% year-on-year to $345 million. This increase was led by 22% growth in clinical development and 16% growth in central laboratories, which more than offset a decline in our market access services. Late-Stage Development pro forma operating margins increased 130 basis points both year-on-year and sequentially to 21.3%.  In Early Development, pro forma revenue of $216 million and pro forma operating margin of 12.0% declined modestly from the third quarter level on lower demand for discovery support services.

"Looking ahead to 2013, for the full year, we are forecasting mid- to high-single digit year-on-year revenue growth and pro forma diluted earnings per share, which exclude costs from ongoing restructuring activities, in the range of $2.85 to $3.15 (assuming foreign exchange rates remain at year-end 2012 levels).  In the first quarter of 2013, we expect revenue to be up slightly from the fourth quarter level and pro forma earnings per share to be in the range of $0.71 to $0.73 as we forecast an increase in Late-Stage Development net revenues and earnings to be off-set by seasonally-lower first quarter Early Development results." 

Consolidated Results($ in millions except EPS)4Q124Q11ChangeFY12FY11ChangeTotal Revenues

$609.1

$582.4$2,365.7

$2,236.4Less: Reimbursable Out-of-Pockets 

$46.9

$49.9$185.1

$140.5Net Revenues

$562.2

$532.5

5.6%

$2,180.6

$2,095.9

4.0%Operating Income

$43.1

$39.0

10.6%

$115.9

$180.6

(35.8%)Operating Margin

7.7%

7.3%5.3%

8.6%Net Income

$33.9

$21.1

60.3%

$94.7

$132.2

(28.3%)Diluted Earnings per Share

$0.61

$0.35

77.5%

$1.68

$2.16

(22.2%)Revenue from
'/>"/>

SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- ChemImage will present a workshop focused on ... Forensic Science Society,s 22 nd International Symposium ... Australia .  Forensic Scientists will be in ... imaging can bring to examination procedures. ... Product Development at ChemImage, will host a workshop ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... that results from the REMEDEE study ( R andomized ... inal sirolimus coat ED bio- E ... Therapy Stent is non-inferior to the TAXUS® Liberte® paclitaxel-eluting stent, with ... results were presented by Michael Haude, M.D., director of Medical Clinic ...
... University Hospitals (UH) Case Medical Center, Case Western ... today the initiation of a novel Phase I clinical ... hematopoietic stem cells (HSCs) from the dose limiting toxicity ... Americans are diagnosed with glioblastoma every year and only ...
Cached Medicine Technology:REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 2REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 3REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 4Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 3Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 4
(Date:8/30/2014)... 30, 2014 The establishment and ... has been one of the main strategies of ... a positive impact around the world. , Architecturally ... top trained executives and trainers deliver L. Ron ... Vital statistics demonstrate that significant reduction in ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all ... Alzheimer’s Disease, Dementia, and Memory Loss . , Country ... being diagnosed with the Alzheimer’s, inspired Seniors Guide writers to ... The movie, out on October 14, 2014, shows a ... of the disease – which inspires a final tour from ...
(Date:8/30/2014)... Randy Dotinga HealthDay Reporter ... one in five patients operated on for broken bones or ... a new study finds. Less-educated patients and patients ... likely to be "doctor shoppers," said study lead author Dr. ... Overall, he said, the study suggests that doctors aren,t talking ...
(Date:8/30/2014)... Administration of colchicine, a plant-based medication commonly used ... showed mixed results in reducing potential complications from ... the risk of gastrointestinal adverse effects, according to ... study is being released early online to coincide ... Cardiology Congress. , Common complications after cardiac surgery ...
(Date:8/30/2014)... 30, 2014 Bringing forth the great ... announces the Labor Day discount on all SEO ... get the complete services related to internet marketing. Their ... Writers, and others do have a deep understanding for ... in their work and since the inception, they have ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
... simple sugar is in fact a critical regulator of ... when disturbed, this process could contribute to cancer or ... and timing of cell division, the researchers say. , ... used inside cells to modify proteins, turning the proteins ...
... range of user-controlled products that would help women protect ... be developed in any form that is convenient to ... ,These microbicides will enable women to negotiate ... at risk and would also help avoid unwanted pregnancies, ...
... a rare, benign intra-articular lesion of unknown aetiology. //It ... synovium, and forms part of the differential diagnosis for ... 50 cases of Lipoma arborescens have previously been reported, ... of other joints including the hip, shoulder, wrist and ...
... continues to grow and currently affects more that ... emphasize a need for alternative diabetes therapies with ... ,The delivery of insulin by the lung may ... diabetes. However, alternative insulin delivery systems must meet ...
... successful completion of Phase II clinical trials of a novel ... suppressing the immune system has been announced by Researchers at ... chronic, painful disease affecting millions worldwide. It is thrice more ... age. It strikes joints on both sides of the body, ...
... to hold on to technological advancements belived to revolutionise ... of computers to improve the quality and effectiveness of ... has now been proved with authencity that even pateints ... successfully educated about health topics using computers that can ...
Cached Medicine News:Health News:Sugar Helps Control Cell Division 2Health News:Lipoma Arborescens: A Rare Tumor Of The Knee 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Novel drug holds promise for treatment of Rheumatoid Arthritis 2Health News:Computers Can Teach Patients About Screening for Cancer 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... System is a panel mounted system that offers ... needs of the heath care professional using the ... available with a dual action lever that allows ... to an IV pole. Similarly, it features ...
Medicine Products: